GSK241220C47000
- 0.00
- 0.000.00%
GlaxoSmithKline Newsroom
GSK's Jemperli Recommended for Expanded Approval in Endometrial Cancer, Receives Breakthrough Therapy Designation for Rectal Cancer
GSK Passes Three Significant Milestones With New Cancer Drug Given a Double Boost | LSE:GSK, NYSE:GSK
GSK's Rectal Cancer Treatment Receives Breakthrough Designation From US FDA
GSK's Cancer Drug Jemperli Moves a Step Closer to European Marketing Permission
United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
Barclays Remains a Hold on GlaxoSmithKline (GSK)
Top Gap Ups and Downs on Wednesday: MLI, MSTR, GSK and More
Anaptys Scraps Development of ANB032, Stock Plunges 33%
TD Cowen Maintains GlaxoSmithKline(GSK.US) With Hold Rating, Maintains Target Price $45
GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex
India Drug Delivery Devices Market 2024, With Profiles of Pfizer, Novartis, GlaxoSmithKline, India Medtronic, Cardinal Health, B. Braun Medical, Sun Pharmaceutical, 3M, Cipla & Bayer Zydus Pharma
GSK, Relation Therapeutics Partner to Advance Osteoarthritis, Fibrotic Disease Treatments
Glaxosmithkline (GSK.US) drugs reduce the risk of death by 42% in multiple myeloma studies.
Glaxosmithkline (GSK.US) reported that a study shows its drug belantamab mafodotin can reduce the risk of death for patients with multiple myeloma at first relapse or post-relapse by 42%.
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Sector Update: Health Care
GSK's DREAMM-7 Trial Shows Sustained Overall Survival Benefit For Belantamab Mafodotin Combination Versus Daratumumab Combination; Benefit Seen Early And Maintained Through Follow-up, Reducing The Risk Of Death By 42% In Multiple Myeloma At Or After...
GSK: Data Compares With Competitor Drug Johnson & Johnson's Darzalex
GSK: Data Supports Potential for Blenrep Combinations to Become Standard of Care